Related Experiment Video
Updated: Aug 8, 2026
08:06
Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model
Published on: November 26, 2010
Adoptive cellular immunotherapy for non-small cell lung cancer: a pilot study
Cytotherapy
|May 15, 2003
Summary
This study shows that combining autologous tumor cell vaccination with ex vivo expanded T cells is a safe and effective adoptive cellular immunotherapy for advanced non-small-cell lung cancer (NSCLC), improving survival rates.
Area of Science:
- Oncology
- Immunotherapy
- Cellular Therapy
Background:
- Autologous tumor cell vaccination followed by ex vivo T cell expansion is a viable experimental strategy.
- This study applies this cellular therapy to late-stage non-small-cell lung cancer (NSCLC).
Purpose of the Study:
- To evaluate the feasibility and efficacy of autologous tumor cell vaccination combined with ex vivo expanded T cells in patients with advanced NSCLC.
Main Methods:
- Twenty-one patients with Stages III and IV NSCLC received vaccinations with irradiated tumor cells and GM-CSF.
- Lymphocytes were collected and ex vivo expanded using IL-2 and anti-CD3 antibody.
- Expanded T cells were re-infused into patients.
Main Results:
- Successful vaccine preparation from 12/16 biopsies.
- 19/21 patients showed a delayed type hypersensitivity response.
- Ex vivo expansion yielded >1.6 x 10(10) cells in 18/21 patients.
- Median survival was 18.6 months with 1-year survival of 51.6%.
Conclusions:
- Autologous tumor cell vaccination combined with ex vivo lymphocyte expansion is a promising adoptive cellular immunotherapy for advanced NSCLC.
- This approach demonstrated favorable overall survival in a poor-prognosis patient cohort.
